Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis.
Ahmed A, Chang CC.
Arch Pathol Lab Med. 2006 Aug;130(8):1133-43. doi: 10.5858/2006-130-1133-CIM.
[Myelofibrosis: A review].
Genthon A, Killian M, Mertz P, Cathebras P, Gimenez De Mestral S, Guyotat D, Chalayer E.
Rev Med Interne. 2021 Feb;42(2):101-109. doi: 10.1016/j.revmed.2020.08.018. Epub 2020 Nov 23.
Myelofibrosis biology and contemporary management.
Gangat N, Tefferi A.
Br J Haematol. 2020 Oct;191(2):152-170. doi: 10.1111/bjh.16576. Epub 2020 Mar 20.
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A.
Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2.
Hematopathologic findings in chronic idiopathic myelofibrosis.
Thiele J, Kvasnicka HM.
Semin Oncol. 2005 Aug;32(4):380-94. doi: 10.1053/j.seminoncol.2005.04.010.
Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.
Mahmud M, Vasireddy S, Gowin K, Amaraneni A.
Int J Mol Sci. 2023 Dec 12;24(24):17383. doi: 10.3390/ijms242417383.
Advances in the therapy of chronic idiopathic myelofibrosis.
Arana-Yi C, Quintás-Cardama A, Giles F, Thomas D, Carrasco-Yalan A, Cortes J, Kantarjian H, Verstovsek S.
Oncologist. 2006 Sep;11(8):929-43. doi: 10.1634/theoncologist.11-8-929.
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
Garmezy B, Schaefer JK, Mercer J, Talpaz M.
Blood Rev. 2021 Jan;45:100691. doi: 10.1016/j.blre.2020.100691. Epub 2020 Apr 7.
Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders.
Lichtman MA.
Leukemia. 2005 Jul;19(7):1139-41. doi: 10.1038/sj.leu.2403804.
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Thiele J, Kvasnicka HM, Schmitt-Gräff A, Hülsemann R, Diehl V.
Histol Histopathol. 2004 Jan;19(1):239-50. doi: 10.14670/HH-19.239.
